Millie
your market intelligence analyst
Search Results
61 results
Your search is now limited to «Clinical Trials» expert search.
GlobeNewswire 07/23/2019 07:01
About the Phase 3 PROTECTOR Program The Phase 3 PROTECTOR program includes two randomized, double-blind, placebo-controlled clinical trials: PROTECTOR 1 and PROTECTOR 2.
More from GlobeNewswire:
ClinicalTrials.gov 07/22/2019 10:23
Condition : Ebola Virus Disease Intervention : Drug: Ad26.ZEBOV/MVA-BN-Filo Sponsors : MRC/UVRI Uganda Research Unit on Aids; Epicentre, Paris, France and Mbarara, Uganda; Janssen Pharmaceutica N.V., Belgium; Coalition for Epidemic Preparedness Innovations Not yet recruiting.
More from ClinicalTrials.gov:
Paula Williamson has received income from AbbVie (AbbVie Inc., IL, USA) related to fees for the preparation of a clinical study report for the randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis-associated uveitis (SYCAMORE.
PR Newswire 07/16/2019 07:30
Recent studies state that industry-sponsored trials yield positive results compared to academic-run trials, which also account for a significant share of clinical trial spending.
More from PR Newswire:
Benzinga 07/15/2019 16:05
William H. Collier, President and Chief Executive Officer of Arbutus, stated, "Preliminary results from this first Phase 1a/1b clinical trial demonstrate that AB-506 is a potent oral capsid inhibitor.
More from Benzinga:
Business Wire 07/12/2019 08:00
UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy.
More from Business Wire:
PharmiWeb.com 06/22/2019 21:38
We are excited to share these first Phase 2 data from our current immuno-oncology pipeline, and also the first data suggesting clinical activity of combining our targeted immunotherapy with standard of care,” said Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic ...
More from PharmiWeb.com:
This pivotal Phase 3 program consists of two studies, the PROTECT study and the CONSTANT study.
More from Middle East North Africa Financial Network (MENAFN):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications